Torrent Pharmaceuticals Limited has informed the Exchange about Investor Presentation
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharmaceuticals has submitted its investor presentation covering unaudited consolidated financial results for Q3 FY26 and the nine months ended December 2025. Total revenue for Q3 FY26 stood at Rs 3,303 crore, up 18% year-on-year from Rs 2,809 crore, driven by strong growth across all key markets. India led with Rs 1,798 crore (14% growth), followed by the US at Rs 321 crore (19%), Germany at Rs 304 crore (8%), and Brazil at Rs 371 crore (27%). For the nine-month period, total revenue grew 14% to Rs 9,783 crore from Rs 8,557 crore, with Brazil and Others showing particularly strong momentum.
Broad-based revenue growth across geographies, especially in Brazil and emerging markets, signals healthy business momentum and could be viewed positively by investors. The absence of margin or guidance commentary in this filing means investors should look to the actual results announcement for profitability insights.